According to one recent cost-effectiveness analysis, the addition of NPH insulin to metformin and sulfonylurea combination therapy is the most cost-effective strategy; however, the use of a DPP-4 inhibitor is potentially cost-effective when higher rates of hypoglycemia are assumed [5]. Here, DPP4 is linked to Hypoglycemia.